Study on the application of Ruxolitinib cream in patients with rash under anti-PD1 cancer therapy
Résumé de l'étude
Rash under tumor treatment with immunotherapy (anti-PD1 antibody therapy) is a common side effect. When such a skin reaction occurs, patients typically suffer from a rash on the chest, back, and extremities. The skin reaction is usually treated with cortisone as a cream or tablet. There is already research on humans regarding the skin reaction under anti-PD1 antibody therapy. Previous studies in humans have shown that certain inflammatory markers are elevated. We also know that the study medication may help reduce these inflammatory markers. However, we do not yet have data on whether the study medication can actually reduce inflammation in the skin in cases of rash under anti-PD1 antibody therapy. Therefore, we are investigating in this study whether the study medication is effective and well tolerated in cases of rash under anti-PD1 antibody therapy. The study medication contains the active ingredient Ruxolitinib and is applied as a cream. The study medication is approved for other skin diseases (vitiligo and atopic eczema) in the USA and in EU countries, respectively only in the USA. Approval in Switzerland is still pending. Only when the efficacy of the study medication against rashes under anti-PD1 antibody therapy is scientifically investigated and proven can it be approved in Switzerland and used as a treatment. In our study, participants will not be divided into groups. Each study patient will receive the investigational substance.
(BASEC)
Intervention étudiée
Topical application of 1.5% INCB18424 (Ruxolitinib cream) twice daily on lesional skin over 12 weeks
(BASEC)
Maladie en cours d'investigation
Lichenoid rashes under anti-PD1 tumor therapy
(BASEC)
- Indication: lichenoid rash that developed under / after anti-PD-1 therapy - Male and female patients aged ≥18 years - The participant has been informed and has given their consent to the IRB/IEC approved informed consent form (BASEC)
Critères d'exclusion
- Patient with other skin diseases resembling lichenoid rashes under anti-PD-1 therapy - Pregnant or breastfeeding women - Topical glucocorticoids, topical calcineurin inhibitors, UV light therapy, therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine are not allowed during the study or in the 8 weeks prior to the start of the study (BASEC)
Lieu de l’étude
Zurich
(BASEC)
Sponsor
Universitätsspital Zürich
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Barbara Meier-Schiesser
+41-43-2539439
barbara.meier-schiesser@clutterusz.chUniversitätsspital Zürich
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
09.02.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Topical Ruxolitinib as a treatment of anti-PD1 induced lichenoid skin toxicities: a prospective single-center pilot study (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible